BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line …
Over the last 12 months, insiders at BioLife Solutions, Inc. have bought $0 and sold $4.13M worth of BioLife Solutions, Inc. stock.
On average, over the past 5 years, insiders at BioLife Solutions, Inc. have bought $43.05M and sold $53.12M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 927,165 shares for transaction amount of $10.37M was made by Casdin Partners Master Fund, L.P. (10 percent owner) on 2023‑10‑19.
2024-11-18 | Sale | EVP & Chief Scientific Officer | 17,604 0.0372% | $20.05 | $352,960 | +24.51% | ||
2024-11-15 | Sale | EVP & Chief Scientific Officer | 25,000 0.0532% | $21.17 | $529,150 | +20.79% | ||
2024-11-12 | Sale | EVP & Chief Scientific Officer | 123 0.0003% | $26.34 | $3,240 | -5.62% | ||
2024-11-12 | Sale | Chief Quality and Operations | 66 0.0001% | $26.34 | $1,738 | -5.62% | ||
2024-11-12 | Sale | Chief Financial Officer | 147 0.0003% | $26.19 | $3,850 | -5.62% | ||
2024-11-12 | Sale | Chief Marketing Officer | 91 0.0002% | $26.34 | $2,397 | -5.62% | ||
2024-10-30 | Sale | EVP & Chief Scientific Officer | 547 0.0011% | $23.15 | $12,663 | +6.23% | ||
2024-10-30 | Sale | Chief Quality and Operations | 277 0.0006% | $23.15 | $6,413 | +6.23% | ||
2024-10-30 | Sale | Chief Financial Officer | 894 0.0019% | $23.15 | $20,696 | +6.23% | ||
2024-10-30 | Sale | Chief Marketing Officer | 311 0.0006% | $23.15 | $7,200 | +6.23% | ||
2024-10-30 | Sale | Chief Human Resources Officer | 203 0.0004% | $23.15 | $4,699 | +6.23% | ||
2024-10-16 | Sale | EVP & Chief Scientific Officer | 10,000 0.0208% | $23.17 | $231,700 | +7.02% | ||
2024-10-15 | Sale | EVP & Chief Scientific Officer | 10,000 0.0209% | $23.28 | $232,800 | +2.86% | ||
2024-09-19 | Sale | EVP & Chief Scientific Officer | 10,000 0.0215% | $25.47 | $254,700 | -6.20% | ||
2024-09-18 | Sale | EVP & Chief Scientific Officer | 10,000 0.0218% | $23.90 | $239,000 | +1.77% | ||
2024-09-16 | Sale | EVP & Chief Scientific Officer | 343 0.0007% | $25.12 | $8,616 | -5.30% | ||
2024-09-16 | Sale | Chief Quality and Operations | 267 0.0006% | $25.12 | $6,707 | -5.30% | ||
2024-09-16 | Sale | Chief Financial Officer | 611 0.0013% | $25.12 | $15,348 | -5.30% | ||
2024-09-16 | Sale | Chief Revenue Officer | 3,070 0.0066% | $25.12 | $77,118 | -5.30% | ||
2024-09-16 | Sale | Chief Marketing Officer | 367 0.0008% | $25.12 | $9,219 | -5.30% |
Mathew Aby J. | EVP & Chief Scientific Officer | 284442 0.6132% | $26.01 | 1 | 115 | <0.0001% |
Casdin Partners Master Fund, L.P. | 10 percent owner | 8557165 18.4473% | $26.01 | 14 | 0 | +28.34% |
VILLIGER WALTER | 10 percent owner | 3281778 7.0747% | $26.01 | 14 | 45 | <0.0001% |
Rice Michael | 347085 0.7482% | $26.01 | 2 | 123 | <0.0001% | |
GIRSCHWEILER THOMAS | director | 47774 0.103% | $26.01 | 2 | 7 |
Casdin Capital | $161.52M | 18.9 | 8.71M | 0% | +$0 | 7.98 | |
BlackRock | $101.34M | 11.86 | 5.46M | +0.72% | +$720,741.70 | <0.01 | |
The Vanguard Group | $53.21M | 6.23 | 2.87M | +11.54% | +$5.5M | <0.01 | |
Millennium Management LLC | $33.63M | 3.94 | 1.81M | -21.6% | -$9.27M | 0.02 | |
William Blair Investment Management | $32.03M | 3.75 | 1.73M | +0.81% | +$255,711.75 | 0.08 |